• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 214

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a Third” of Her Workload; Ipsos/Psychedelic Alpha Poll; Reunion Eyes Single Phase 3 in...

Joshua White – Fireside Project and Lucy, an AI Training Simulator for Psychedelic Support

Did New Jersey Really Just Legalize Psilocybin?

Psychedelic Funding, Public Markets, and M&A in 2025

Op-Ed: Beyond Clinical Trials: Psychedelic-Assisted Therapy in Europe’s Real World

Cybin Hosting Research and Development Briefing on November 8, 2021

Filament Health Announces FDA Authorization of Clinical Trial with First-Ever Direct...

Field Trip Health Ltd. Schedules Second Fiscal Quarter 2022 Financial Results...

Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in...

PT269 – Adam Strauss – Comedy, OCD, and The Mushroom Cure

Psychedelic Research Bulletin: October 2021

The Compounds in Psychedelic Cacti

atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort...

Red Light Holland Appoints New Chief Financial Officer

PharmaDrug Expands Product Offering to Prepare for Potential Adult Use Market...

1...213214215...306Page 214 of 306

EDITOR PICKS

Pα+ Psychedelic Bulletin #218: FDA’s Farchione Says Psychedelic INDs Are “a...

Joshua White – Fireside Project and Lucy, an AI Training Simulator...

Did New Jersey Really Just Legalize Psilocybin?

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©